Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA3 | P42263 | 1/20 | 0.57 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637281 | 0.94 | GRIA3 (0.55) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL637584 | 0.92 | GRIA3 (0.56) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL10032960 | 0.88 | GRIA3 (0.60) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL548676 | 0.84 | GRIA3 (0.59) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL548631 | 0.82 | GRIA3 (0.53) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL548619 | 0.82 | GRIA3 (0.53) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL10001645 | 0.81 | GRIA3 (0.52) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL548639 | 0.80 | GRIA3 (0.51) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL2918994 | 0.78 | GRIA3 (0.52) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL10001644 | 0.76 | GRIA3 (0.47) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168632-B2 | Bicyclic amide derivatives for the treatment of respiratory disorders | CORTEX PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | claimed |
| US-8119632-B2 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | claimed |
| WO-2010087980-A2 | BICYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DEPRESSION | CORTEX PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| US-20100173903-A1 | Bicyclic amide derivatives for the treatmet of respiratory disorders | CORTEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| US-20100173902-A1 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICAL, INC. (US) | 2010-07-08 | — | — | US | claimed |
| US-8507482-B2 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507482-B2 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507482-B2 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120122861-A1 | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122861-A1 | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122861-A1 | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8168632-B2 | Bicyclic amide derivatives for the treatment of respiratory disorders | CORTEX PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8119632-B2 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2391621-A2 | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010087981-A2 | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010087981-A2 | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100173903-A1 | Bicyclic amide derivatives for the treatmet of respiratory disorders | CORTEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173903-A1 | Bicyclic amide derivatives for the treatmet of respiratory disorders | CORTEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173902-A1 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICAL, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173902-A1 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICAL, INC. (US) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122861-A1 | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN1, GRIN2A, BDNF | GRIA3 20/4885GRIA4 24/4885EPHX2 1071/4885 |
| US-20100173903-A1 | Bicyclic amide derivatives for the treatmet of respiratory disorders | ABAT, COX6A1, OAT | GRIA3 536/4885GRIA4 968/4885EPHX2 2628/4885 |
| US-20100173902-A1 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | HCRTR2, CHAT, GRIN1 | GRIA3 29/4885GRIA4 70/4885EPHX2 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.